Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling

Table 8 Predicted time to recrudescence (in days) for dihydroartemisinin-piperaquine (DHA-PPQ) in populations of 10,000 individuals for different treatment scenarios group by dosing regimen (according to Table 2 ) and geographical region

Treatment scenario		Age-based dosing regimen				Weight-based dosing regimen
Full course, i e, once daily over three days at 0, 24 and 48 hours	Min.	5	5	5	5	7	6	5	6
	1st Qu.	18	17	18	19	25	25	25	26
	Median	25	25	26	27	34	34	34	32
	Mean	27	27	27	28	36	35	35	33
	3rd Qu.	35	35	35	36	47	45	46	41
	Max.	63	62	63	63	63	63	63	63
Second dose missed	Min.	5	5	5	5	5	5	5	5
	1st Qu.	13	14	14	14	21	21	22	21
	Median	23	23	22	23	29	29	29	29
	Mean	24	24	24	25	31	30	31	30
	3rd Qu.	33	32	32	33	40	38	39	37
	Max.	63	63	63	63	62	63	63	63
Third dose missed	Min.	4	4	4	4	4	4	4	4
	1st Qu.	12	13	13	13	21	20	21	20
	Median	22	22	21	22	29	29	29	29
	Mean	23	23	23	23	30	29	30	29
	3rd Qu.	31	31	31	32	39	38	39	37
	Max.	63	63	63	63	63	63	63	63
Second and third dose missed	Min.	3	3	3	3	3	3	3	3
	1st Qu.	7	7	7	7	12	11	12	11
	Median	15	15	15	16	21	21	22	21
	Mean	19	18	18	19	23	22	23	22
	3rd Qu.	28	27	28	28	32	31	32	31
	Max.	63	63	63	63	63	63	63	63
Second and third dose delayed by 24 hours	Min.	6	6	6	6	7	6	7	8
	1st Qu.	18	18	19	20	25	25	24	25
	Median	26	27	27	28	34	34	34	33
	Mean	27	28	28	29	36	35	35	33
	3rd Qu.	35	36	36	37	48	45	47	41
	Max.	63	63	63	63	63	63	63	63

ISSN: 1475-2875